Drug combination can also overcome the resistance of pancreatic cancer to PD-1/PD-L1 monotherapy and promote the transformation of tumor biological behavior from nonimmunological to immunological, which maximizes the antitumor therapeutic effects of immunosuppressants [29]. The gene discussed is CD274; the disease is neoplasm.